Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
Public ClinicalTrials.gov record NCT00035555. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II/III, Open-Label, Randomized, Controlled, Multiple-Dose Study of Efficacy and Safety of BMS-224818 (Belatacept) as Part of a Quadruple Drug Regimen in First Renal Transplant Recipients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether treatment with Belatacept (BMS-224818) is as efficacious as treatment with cyclosporine at preventing acute rejection and with a superior safety/tolerability profile (better kidney function and blood pressure, fewer lipid problems, less diabetes mellitus).
Study identification
- NCT ID
- NCT00035555
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 230 participants
Conditions and interventions
Interventions
- Belatacept Drug
- Cyclosporine Drug
- Mycophenolate mofetil (MMF) Drug
- Corticosteroids Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2001 (Type not available)
- Primary completion
- Jan 2004 (Actual)
- Completion
- Jul 2012 (Actual)
- Last update posted
- Jan 13, 2014
2001 – 2012
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ. of Calif. - San Francisco | San Francisco | California | 94143-0001 | — |
| Emory Univ. School of Medicine | Atlanta | Georgia | 30322 | — |
| Johns Hopkins University | Baltimore | Maryland | 21205 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Univ. of Nebraska Medical Center | Omaha | Nebraska | 68198-1002 | — |
| Saint Barnabas Medical Center | Livingston | New Jersey | 07039 | — |
| Mount Sinai Medical Center | New York | New York | 10029-6574 | — |
| Univ. of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Medical Univ. of South Carolina | Charleston | South Carolina | 29425 | — |
| Baylor Univ. Medical Center | Dallas | Texas | 75246 | — |
| Univ. of Wisconsin | Madison | Wisconsin | 53792-7375 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00035555, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2014 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00035555 live on ClinicalTrials.gov.